Treatment of amyloidosis

American Journal of Kidney Diseases

Volumn 26, Issue 2, 1995, Pages 267-285

  Tan, S Y ^a   Pepys, M B ^a   Hawkins, P N ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Amyloid; amyloidosis; regression; scintigraphy; treatment

Indexed keywords

AMYLOID A PROTEIN; AMYLOID PRECURSOR PROTEIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; PREDNISONE;

AMYLOID NEUROPATHY; AMYLOIDOSIS; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DISEASE CLASSIFICATION; FAMILIAL DISEASE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; REVIEW; RHEUMATOID ARTHRITIS; SCINTIGRAPHY;

AMYLOIDOSIS; HUMAN; SUPPORT, NON-U.S. GOV'T;

EID: 0029155934     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/0272-6386(95)90647-9     Document Type: Review

References (123)

1. Amyloidosis
2. Nomenclature and classification of amyloid and amyloidoses
3. Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils
4. Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits
5. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure
6. Diagnostic radionuclide imaging of amyloid: Biological targeting by circulating human serum amyloid P component
7. 123I-labeled serum amyloid P component
8. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis
9. Dialysis-related amyloidosis
10. Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis
11. Natural history and regression of amyloidosis
12. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression
13. Regression of AL amyloidosis and prolonged survival following cardiac transplantation and chemotherapy
14. Evaluation of 100 cases of systemic AL amyloidosis by serum amyloid P component (SAP) scintigraphy
15. 123I-SAP scintigraphy
16. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis
17. The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo
18. 131I-beta 2-microglobulin
19. Diagnosis and monitoring of amyloidosis
20. 99mTc-labelled serum amyloid P component
21. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation
22. Fifteen years' experience with renal transplantation in systemic amyloidosis
23. Renal transplantation in 45 patients with amyloidosis
24. Renal transplantation in patients with amyloidosis due to familial Mediterranean fever
25. Factor X deficiency in primary amyloidosis: Resolution after splenectomy
26. Colchicine for familial Mediterranean fever
27. Colchicine in the prevention and treatment of amyloidosis of familial Mediterranean fever
28. Colchicine in the treatment of AA and AL amyloidosis
29. Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever
30. Secondary systemic amyloidosis: Response and survival in 64 patients
31. Amyloidosis in juvenile chronic polyarthritis
32. Alkylating cytostatic treatment in renal amyloidosis secondary to rheumatic disease
33. Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency
34. Treatment of amyloidosis secondary to rheumatoid arthritis with cyclophosphamide
35. Amyloidosis in juvenile chronic arthritis: A morbidity and mortality study
36. Results, principles and pitfalls in the management of renal AA amyloidosis; a 10–21 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics
37. Prolonged colchicine treatment in four patients with amyloidosis
38. Long term colchicine treatment in children with familial Mediterranean fever
39. Colchicine treatment in conception and pregnancy: Two hundred thirty one pregnancies in patients with familial Mediterranean fever
40. Regression of amyloidosis secondary to granulomatous ileitis following surgical resection and colchicine administration
41. Regression of reactive systemic amyloidosis due to ankylosing spondylitis following the administration of colchicine
42. Amyloidosis and inflammatory bowel disease
43. Colchicine and secondary amyloidosis
44. Remission of nephrotic syndrome in amyloidosis associated with a hypernephroma
45. Remission of nephrotic syndrome related to AA amyloidosis after hepatic adenomectomy
46. Rapid regression of AA amyloidosis following surgery for Castleman's disease
47. Regression of amyloid in Crohn's disease after bowel resection
48. Amyloidosis (AA type) with gastrointestinal involvement: Resolution of gastric amyloid deposition in parallel with disappearance of the serum component of amyloid A protein
49. Rapid automated enzyme immunoassay of serum amyloid A
50. Amyloidosis: Review of 236 cases
51. Amyloidosis (AL): Clinical and laboratory features in 229 cases
52. Primary systemic amyloidosis: Multivariate analysis for prognostic factors in 168 cases
53. Primary systemic amyloidosis: Comparison of melphalan and prednisone versus placebo
54. Amyloidosis of the AL type
55. Primary systemic amyloidosis
56. Treatment of “primary” renal amyloidosis with melphalan
57. Response of primary hepatic amyloidosis to melphalan and prednisone: A case report and review of the literature
58. Treatment of AL amyloidosis with melphalan, prednisone, and colchicine
59. Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy
60. Effect of colchicine on experimental amyloidosis in two CBA/J mouse models
61. Survival of patients with primary (AL) amyloidosis
62. Primary systemic amyloidosis
63. Primary systemic amyloidosis (AL): Randomized trial of colchicine vs melphalan and prednisolone vs melphalan, prednisolone and colchicine
64. Treatment of patients with primary amyloidosis
65. Response rates and survival in primary systemic amyloidosis
66. Treatment of AL amyloidosis without myeloma
67. High-dose therapy and autologous transplantation in amyloidosis-AL
68. Comparison of histology with SAP scintigraphy for evaluation of amyloidosis
69. Renal replacement therapy in multiple myeloma and systemic amyloidosis
70. Dialysis support of patients with primary systemic amyloidosis
71. Chronic dialysis in patients with systemic amyloidosis: The experience in northern Italy
72. End-stage renal disease in systemic amyloidosis: Clinical course and outcome on dialysis
73. Cardiac transplantation in AL amyloidosis: Experience in three patients
74. Factor X deficiency in amyloidosis A critical review
75. Resolution of factor X deficiency in primary amyloidosis following splenectomy
76. 2-microglobulin
77. Systemic involvement of dialysis-amyloidosis
78. Rheumatic syndromes and beta 2-microglobulin amyloidosis in patients receiving long-term peritoneal dialysis
79. Beta 2-microglobulin amyloidosis in a patient treated exclusively by continuous ambulatory peritoneal dialysis
80. Beta 2-microglobulin amyloidosis in chronic renal failure
81. Turnover in humans of beta 2-microglobulin: The constant chain of HLA-antigens
82. Hemodialysis versus CAPD: Equal predisposition to amyloidosis?
83. Can the nephrologist prevent dialysis-related amyloidosis?
84. 2-microglobulin
85. 2-microglobulin in tissues causes amyloidosis in patients on chronic hemodialysis
86. Beta 2-microglobulin serum concentration and associated amyloidosis in dialysis patients
87. Beta 2-microglobulin amyloidosis: A sternoclavicular joint biopsy study in hemodialysis patients
88. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis
89. Case control study on dialysis arthropathy: The influence of two different dialysis membranes: Data from the EDTA Registry
90. 131I-serum amyloid P component
91. Stimulation of beta 2-microglobulin synthesis in lymphocytes after exposure to Cuprophan dialyzer membranes
92. Is tumour necrosis factor produced in the peritoneal cavity of asymptomatic CAPD patients?
93. Endoscopic management of shoulder pain in long-term hemodialysis patients
94. Influence of hemodialysis membranes on beta 2-microglobulin kinetics: In vivo and in vitro studies
95. 2-Microglobulin kinetics during hemofiltration
96. A new therapeutic approach to dialysis amyloidosis: Intensive removal of beta 2-microglobulin with adsorbent column
97. Effect of renal transplantation on the radiological signs of dialysis amyloid osteoarthropathy
98. Carpal tunnel syndrome and type of dialysis membrane
99. Influence of dialysis membranes on the development of dialysis associated osteoarthropathy
100. Low prevalence of carpal tunnel syndrome in patients haemodialysed with highflux membrane
101. Long-term complications of dialysis: Pathogenic factors with special reference to amyloidosis
102. Rheumatologic and radiologic symptoms of dialysis-associated beta 2-microglobulin amyloidosis: Long-term retrospective study of 175 chronic hemodialysis patients
103. Using ultrapure water in hemodialysis delays carpal tunnel syndrome
104. Dialysis-related amyloidosis during peritoneal dialysis
105. Dialysis amyloidosis
106. Renal transplantation for dialysis amyloidosis
107. Does dialysis-associated amyloidosis resolve after transplantation?
108. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy
109. Homozygosity for the TTR-Met30-gene in a 56 year-old Swedish man
110. 30)
111. Liver transplantation as a treatment for familial amyloidotic polyneuropathy
112. Familial amyloidotic polyneuropathy type I (Andrade's disease): A new indication for liver transplant
113. World-wide survey of liver transplantation in patients with familial amyloidotic polyneuropathy
114. Clinical phenotypes in familial amyloid polyneuropathy associated with new transthyretin variants Va147 and Pro52
115. CAPD and systemic diseases
116. Continuous ambulatory peritoneal dialysis in systemic amyloidosis and end-stage renal disease
117. Use of peritoneal dialysis in the treatment of patients with renal failure and paraproteinemia
118. The role of continuous ambulatory peritoneal dialysis in end-stage renal failure due to multiple myeloma
119. Gastrointestinal manifestations of amyloidosis
120. Adrenal dysfunction in patients with renal amyloid
121. Outcome of patients with secondary amyloidosis in dialysis treatment
122. Renal transplantation in amyloidosis
123. The results of transplantation of patients with amyloid nephropathy